BackARS Pharmaceuticals Overview
ARS Pharmaceuticals Inc

ARS Pharmaceuticals Target Price

Where could SPRY trade next? Consensus target price: $15.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.79

Average Target Price

$15.00437.6% upside

1 analysts in the last 4 months

High: $15 | Low: $15

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-08Leerink Partners$15437.6% upsideOpen
2026-04-09Northland Securities$25796.1% upsideOpen
2026-03-10Leerink PartnersRoanna Ruiz$26831.9% upsideOpen
2025-11-04Roth CapitalKyle Bauser$30975.3% upsideOpen
2025-09-26Raymond James$321047% upsideOpen
2024-08-19Cantor FitzgeraldJosh Schimmer$30975.3% upsideOpen
2024-08-12Raymond JamesStrong Buy$22688.5% upsideOpen
2024-07-25Raymond JamesRyan Deschner$18545.2% upsideOpen
2024-03-05Leerink PartnersRoanna Ruiz$18545.2% upsideOpen
2022-12-13Leerink Partners$14401.8% upsideOpen

ARS Pharmaceuticals (SPRY) FAQ

The latest target price for SPRY is $15. Investors often review this figure alongside ARS Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

ARS Pharmaceuticals trades near $2.79 while the consensus target sits at $15 (437.6% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting SPRY's target price ($15), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack ARS Pharmaceuticals's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.